Brief: Paion discontinues European Remimazolam Phase 3 trial
09/02/2016 19:07
Feb 9 (Reuters) - Paion Ag PA8G.DE
* Paion discontinues European Remimazolam Phase III trial in
cardiac surgery patients due to insufficient recruitment
Source text for Eikon: urn:newsml:reuters.com:*:nEQ351Gyka
Further company coverage: PA8G.DE
(Reporting by Frankfurt Newsroom)
((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;))
Recent news on PAION AG
See all newsBrief: Paion AG To Issue Approx 4.8 Mln Shares In Capital Increase With Subscription Rights
Brief: Paion AG Reports Developments On Commercial Activities In Europe
Brief: Paion Q1 EBITDA Up At EUR 15 Mln
Brief: Paion Grants Exclusive License To Cristália For Development And Commercialization Of Remimazolam In Latin America
Brief: Paion Announces Sebastian Werner As New CFO, Effective 1 June 2022